PSTV
Plus Therapeutics, Inc.
Price Chart
Latest Quote
$4.20
-0.11 (-2.55%)
Current Price
| Previous Close | $4.31 |
| Open | $4.38 |
| Day High | $4.38 |
| Day Low | $4.10 |
| Volume | 214,522 |
Stock Information
| Shares Outstanding | 6.88M |
| Total Debt | $725K |
| Cash Equivalents | $15.11M |
| Revenue | $5.18M |
| Net Income | $-11.93M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $28.91M |
| P/E Ratio | 0.20 |
| EPS (TTM) | $21.51 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $14.52M |
| Sales | $5.18M |
| Income | $-11.93M |
| Book/sh | $1.74 |
| Cash/sh | $2.20 |
| Employees | 28 |
Financial Ratios
| Quick Ratio | 2.07 |
| Current Ratio | 2.27 |
| Debt/Eq | 6.06 |
Returns & Margins
| ROA | -73.82% |
| Gross Margin | -83.09% |
| Operating Margin | -692.51% |
| Profit Margin | -230.24% |
Ownership
| Insider Ownership | 1.49% |
| Institutional Ownership | 10.38% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.75 |
| PEG | 2.45 |
| P/S | 5.58 |
| P/B | 2.41 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $36.00 |
Technical Indicators
| SMA20 | $5.57 |
| SMA50 | $5.84 |
| SMA200 | $9.90 |
| RSI | 18.60 |
| ATR | 0.4400 |
| Shares Float | 6.48M |
| Short Float | 16.69% |
| Short Ratio | 7.75 |
| Volatility | 1.37 |
| Rel Volume | 1.42 |
Performance History
| Week | -22.51% |
| Month | -27.96% |
| Quarter | -30.00% |
| 6 Months | -73.75% |
| YTD | -70.00% |
| Year | -45.81% |
| 3 Years | -95.03% |
| 5 Years | -99.61% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $4.20 | 214,500 |
| 2026-06-17 | $4.31 | 177,700 |
| 2026-06-16 | $4.57 | 240,100 |
| 2026-06-15 | $4.85 | 295,700 |
| 2026-06-12 | $5.01 | 97,900 |
| 2026-06-11 | $5.42 | 76,700 |
| 2026-06-10 | $5.39 | 126,300 |
| 2026-06-09 | $5.50 | 108,500 |
| 2026-06-08 | $5.53 | 145,000 |
| 2026-06-05 | $5.41 | 120,100 |
| 2026-06-04 | $5.75 | 103,000 |
| 2026-06-03 | $5.42 | 105,600 |
| 2026-06-02 | $5.47 | 122,100 |
| 2026-06-01 | $5.70 | 118,700 |
| 2026-05-29 | $5.82 | 190,700 |
| 2026-05-28 | $6.43 | 148,400 |
| 2026-05-27 | $6.64 | 107,800 |
| 2026-05-26 | $6.60 | 103,500 |
| 2026-05-22 | $6.59 | 128,300 |
| 2026-05-21 | $6.89 | 286,100 |
| 2026-05-20 | $6.43 | 227,900 |
| 2026-05-19 | $5.83 | 141,900 |
About Plus Therapeutics, Inc.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
đ° Latest News
Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform
Proactive âĸ 2026-06-04T16:17:00Z
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-15T21:20:01Z
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
24/7 Wall St. âĸ 2026-05-14T15:39:27Z
Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings and Revenue Estimates
Zacks âĸ 2026-05-11T22:05:04Z
OmniAb, Inc. (OABI) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-08T02:25:07Z
D. Boral Capital Downgrades Plus Therapeutics (PSTV) to Hold
Insider Monkey âĸ 2026-04-07T14:29:57Z
Plus Therapeutics (PSTV) Reports Break-Even Earnings for Q4
Zacks âĸ 2026-03-12T23:25:02Z
Plus: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-12T22:27:14ZNektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates
Zacks âĸ 2026-03-12T21:35:02Z
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates
Zacks âĸ 2026-02-26T23:00:04Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $3,609,000 | $3,724,000 | $395,000 | $711,000 |
| Total Expenses | $15,298,000 | $14,695,000 | $13,321,000 | $19,712,000 |
| Other Income Expense | $-3,595,000 | $5,168,000 | - | $1,000 |
| Other Non Operating Income Expenses | $-964,000 | $-486,000 | - | $1,000 |
| Net Non Operating Interest Income Expense | $-3,493,000 | $-3,451,000 | $5,000 | $-564,000 |
| Interest Expense Non Operating | $3,609,000 | $3,724,000 | $395,000 | $711,000 |
| Operating Expense | $15,298,000 | $14,695,000 | $13,321,000 | $19,712,000 |
| Other Operating Expenses | $-5,213,000 | $-5,824,000 | $-4,913,000 | $-224,000 |
| General And Administrative Expense | $12,132,000 | $9,939,000 | $8,544,000 | $10,238,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-22,386,000 | $-12,978,000 | $-13,316,000 | $-20,275,000 |
| Net Interest Income | $-3,493,000 | $-3,451,000 | $5,000 | $-564,000 |
| Interest Income | $116,000 | $273,000 | $400,000 | $147,000 |
| Normalized Income | $-19,755,000 | $-18,632,000 | $-13,316,000 | $-20,275,000 |
| Net Income From Continuing And Discontinued Operation | $-22,386,000 | $-12,978,000 | $-13,316,000 | $-20,275,000 |
| Total Operating Income As Reported | $-15,298,000 | $-14,695,000 | $-13,321,000 | $-19,712,000 |
| Average Dilution Earnings | $0 | $-5,047,000 | - | - |
| Net Income Common Stockholders | $-22,386,000 | $-12,978,000 | $-13,316,000 | $-20,275,000 |
| Net Income | $-22,386,000 | $-12,978,000 | $-13,316,000 | $-20,275,000 |
| Net Income Including Noncontrolling Interests | $-22,386,000 | $-12,978,000 | $-13,316,000 | $-20,275,000 |
| Net Income Continuous Operations | $-22,386,000 | $-12,978,000 | $-13,316,000 | $-20,275,000 |
| Pretax Income | $-22,386,000 | $-12,978,000 | $-13,316,000 | $-20,275,000 |
| Interest Income Non Operating | $116,000 | $273,000 | $400,000 | $147,000 |
| Operating Income | $-15,298,000 | $-14,695,000 | $-13,321,000 | $-19,712,000 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-7.25 | $-58.50 | $-106.00 | $-288.75 |
| Basic EPS | $-7.25 | $-48.75 | $-106.00 | $-288.75 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-15,701,000 | $-14,036,000 | $-12,293,000 | $-18,945,000 |
| Total Unusual Items | $-2,631,000 | $5,654,000 | - | $1,000 |
| Total Unusual Items Excluding Goodwill | $-2,631,000 | $5,654,000 | - | $1,000 |
| Reconciled Depreciation | $445,000 | $872,000 | $628,000 | $619,000 |
| EBITDA (Bullshit earnings) | $-18,332,000 | $-8,382,000 | $-12,293,000 | $-18,945,000 |
| EBIT | $-18,777,000 | $-9,254,000 | $-12,921,000 | $-19,564,000 |
| Diluted Average Shares | $3,112,184 | $308,030 | $125,637 | $70,014 |
| Basic Average Shares | $3,112,184 | $265,610 | $125,637 | $70,014 |
| Diluted NI Availto Com Stockholders | $-22,386,000 | $-18,025,000 | $-13,316,000 | $-20,275,000 |
| Gain On Sale Of Security | $-2,631,000 | $5,654,000 | - | $1,000 |
| Research And Development | $8,379,000 | $10,580,000 | $9,690,000 | $9,698,000 |
| Selling General And Administration | $12,132,000 | $9,939,000 | $8,544,000 | $10,238,000 |
| Other Gand A | $12,132,000 | $9,939,000 | $8,544,000 | $10,238,000 |
| Gain On Sale Of Ppe | - | - | - | $0 |
| Salaries And Wages | - | - | - | $519,000 |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $3,291,000 | $-9,790,000 | $-1,762,000 | $5,979,000 |
| Total Assets | $16,325,000 | $6,633,000 | $11,388,000 | $23,867,000 |
| Total Non Current Assets | $1,155,000 | $1,374,000 | $1,554,000 | $2,050,000 |
| Other Non Current Assets | $123,000 | $12,000 | $32,000 | $12,000 |
| Goodwill And Other Intangible Assets | $705,000 | $841,000 | $414,000 | $466,000 |
| Other Intangible Assets | $333,000 | $469,000 | $42,000 | $94,000 |
| Current Assets | $15,170,000 | $5,259,000 | $9,834,000 | $21,817,000 |
| Current Deferred Assets | $394,000 | $436,000 | $234,000 | - |
| Restricted Cash | $4,502,000 | $0 | - | - |
| Prepaid Assets | $1,340,000 | $646,000 | $1,046,000 | $3,697,000 |
| Receivables | $322,000 | $571,000 | $0 | - |
| Other Receivables | $322,000 | $571,000 | - | - |
| Cash Cash Equivalents And Short Term Investments | $8,612,000 | $3,606,000 | $8,554,000 | $18,120,000 |
| Cash And Cash Equivalents | $4,256,000 | $76,000 | $8,554,000 | $18,120,000 |
| Other Current Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $821,000 | $3,367,000 | $4,181,000 | $5,645,000 |
| Long Term Debt And Capital Lease Obligation | $15,000 | $31,000 | $85,000 | $3,927,000 |
| Current Debt And Capital Lease Obligation | $806,000 | $3,336,000 | $4,096,000 | $1,718,000 |
| Current Debt | $750,000 | $3,292,000 | $3,976,000 | $1,608,000 |
| Net Debt | - | $3,216,000 | - | - |
| Other Current Borrowings | - | - | $3,976,000 | $1,608,000 |
| Long Term Debt | - | - | - | $3,786,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $12,329,000 | $15,582,000 | $12,736,000 | $17,422,000 |
| Total Non Current Liabilities Net Minority Interest | $15,000 | $31,000 | $2,009,000 | $5,570,000 |
| Current Liabilities | $12,314,000 | $15,551,000 | $10,727,000 | $11,852,000 |
| Other Current Liabilities | $4,661,000 | - | - | - |
| Current Deferred Liabilities | $927,000 | $927,000 | $0 | - |
| Payables And Accrued Expenses | $5,499,000 | $10,932,000 | $6,261,000 | $9,809,000 |
| Interest Payable | $0 | $117,000 | $0 | - |
| Payables | $3,276,000 | $9,474,000 | $4,758,000 | $8,364,000 |
| Accounts Payable | $3,276,000 | $9,474,000 | $4,758,000 | $8,364,000 |
| Non Current Deferred Liabilities | - | $0 | $1,924,000 | $1,643,000 |
| Derivative Product Liabilities | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $3,996,000 | $-8,949,000 | $-1,348,000 | $6,445,000 |
| Total Equity Gross Minority Interest | $3,996,000 | $-8,949,000 | $-1,348,000 | $6,445,000 |
| Stockholders Equity | $3,996,000 | $-8,949,000 | $-1,348,000 | $6,445,000 |
| Retained Earnings | $-515,865,000 | $-493,479,000 | $-480,501,000 | $-467,185,000 |
| Other | ||||
| Treasury Shares Number | $10,337 | $10,337 | $3,142 | - |
| Preferred Shares Number | $325 | $325 | $325 | $325 |
| Ordinary Shares Number | $5,547,034 | $235,853 | $177,763 | $89,603 |
| Share Issued | $5,557,371 | $246,190 | $180,905 | $89,603 |
| Tangible Book Value | $3,291,000 | $-9,790,000 | $-1,762,000 | $5,979,000 |
| Invested Capital | $4,746,000 | $-5,657,000 | $2,628,000 | $11,839,000 |
| Working Capital | $2,856,000 | $-10,292,000 | $-893,000 | $9,965,000 |
| Capital Lease Obligations | $71,000 | $75,000 | $205,000 | $251,000 |
| Total Capitalization | $3,996,000 | $-8,949,000 | $-1,348,000 | $10,231,000 |
| Treasury Stock | $500,000 | $500,000 | $126,000 | $0 |
| Additional Paid In Capital | $520,222,000 | $485,024,000 | $479,274,000 | $473,628,000 |
| Capital Stock | $139,000 | $6,000 | $5,000 | $2,000 |
| Common Stock | $139,000 | $6,000 | $5,000 | $2,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $15,000 | $31,000 | $85,000 | $141,000 |
| Current Deferred Revenue | $927,000 | $927,000 | $0 | - |
| Current Capital Lease Obligation | $56,000 | $44,000 | $120,000 | $110,000 |
| Line Of Credit | $750,000 | $3,292,000 | $3,976,000 | - |
| Pensionand Other Post Retirement Benefit Plans Current | $421,000 | $356,000 | $370,000 | $325,000 |
| Current Accrued Expenses | $2,223,000 | $1,458,000 | $1,503,000 | $1,445,000 |
| Goodwill | $372,000 | $372,000 | $372,000 | $372,000 |
| Net PPE | $327,000 | $521,000 | $1,108,000 | $1,572,000 |
| Accumulated Depreciation | $-3,335,000 | $-3,140,000 | $-2,536,000 | $-1,960,000 |
| Gross PPE | $3,662,000 | $3,661,000 | $3,644,000 | $3,532,000 |
| Leases | $1,810,000 | $1,810,000 | $1,810,000 | $1,810,000 |
| Other Properties | $70,000 | $73,000 | $202,000 | $248,000 |
| Machinery Furniture Equipment | $1,782,000 | $1,778,000 | $1,632,000 | $1,474,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $4,356,000 | $3,530,000 | $0 | - |
| Non Current Deferred Revenue | - | $0 | $1,924,000 | $1,643,000 |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-20,842,000 | $-11,245,000 | $-13,011,000 | $-13,731,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-20,775,000 | $-10,554,000 | $-12,851,000 | $-12,972,000 |
| Cash Flow From Continuing Operating Activities | $-20,775,000 | $-10,554,000 | $-12,851,000 | $-12,972,000 |
| Operating Gains Losses | $2,615,000 | $-5,654,000 | $2,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-67,000 | $-691,000 | $-160,000 | $-759,000 |
| Investing Cash Flow | $-854,000 | $-4,111,000 | $-160,000 | $-759,000 |
| Cash Flow From Continuing Investing Activities | $-854,000 | $-4,111,000 | $-160,000 | $-759,000 |
| Net Other Investing Changes | - | - | - | $-250,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-374,000 | $-126,000 | $0 |
| Issuance Of Capital Stock | $38,541,000 | $7,265,000 | $5,527,000 | $15,832,000 |
| Financing Cash Flow | $30,311,000 | $6,187,000 | $3,445,000 | $13,451,000 |
| Cash Flow From Continuing Financing Activities | $30,311,000 | $6,187,000 | $3,445,000 | $13,451,000 |
| Net Other Financing Charges | $-5,723,000 | - | $-348,000 | $-773,000 |
| Net Common Stock Issuance | $38,541,000 | $6,891,000 | $5,401,000 | $15,832,000 |
| Common Stock Issuance | $38,541,000 | $7,265,000 | $5,527,000 | $15,832,000 |
| Other | ||||
| Repayment Of Debt | $-6,995,000 | $-3,996,000 | $-1,608,000 | $-1,608,000 |
| Issuance Of Debt | $4,488,000 | $3,292,000 | $0 | - |
| Interest Paid Supplemental Data | $0 | $32,000 | $222,000 | $327,000 |
| End Cash Position | $8,758,000 | $76,000 | $8,554,000 | $18,120,000 |
| Beginning Cash Position | $76,000 | $8,554,000 | $18,120,000 | $18,400,000 |
| Changes In Cash | $8,682,000 | $-8,478,000 | $-9,566,000 | $-280,000 |
| Common Stock Payments | $0 | $-374,000 | $-126,000 | $0 |
| Net Issuance Payments Of Debt | $-2,507,000 | $-704,000 | $-1,608,000 | $-1,608,000 |
| Net Short Term Debt Issuance | $-2,542,000 | $3,292,000 | $0 | - |
| Short Term Debt Payments | $-3,292,000 | $0 | - | - |
| Short Term Debt Issuance | $750,000 | $3,292,000 | $0 | - |
| Net Long Term Debt Issuance | $35,000 | $-3,996,000 | $-1,608,000 | $-1,608,000 |
| Long Term Debt Payments | $-3,703,000 | $-3,996,000 | $-1,608,000 | $-1,608,000 |
| Long Term Debt Issuance | $3,738,000 | $0 | - | - |
| Net Investment Purchase And Sale | $-817,000 | $-3,420,000 | $0 | - |
| Sale Of Investment | $8,536,000 | $12,170,000 | $0 | - |
| Purchase Of Investment | $-9,353,000 | $-15,590,000 | $0 | - |
| Net Intangibles Purchase And Sale | $0 | $-545,000 | $0 | $-250,000 |
| Purchase Of Intangibles | $0 | $-545,000 | $0 | $-250,000 |
| Net PPE Purchase And Sale | $-37,000 | $-146,000 | $-160,000 | $-509,000 |
| Sale Of PPE | $30,000 | $0 | - | $0 |
| Purchase Of PPE | $-67,000 | $-146,000 | $-160,000 | $-509,000 |
| Change In Working Capital | $-6,041,000 | $3,222,000 | $-1,116,000 | $5,597,000 |
| Change In Other Current Liabilities | $93,000 | $-130,000 | $-117,000 | $-129,000 |
| Change In Other Current Assets | $-763,000 | $218,000 | $2,397,000 | $-2,369,000 |
| Change In Payables And Accrued Expense | $-5,620,000 | $4,702,000 | $-3,677,000 | $6,452,000 |
| Change In Receivables | $249,000 | $-571,000 | $0 | - |
| Other Non Cash Items | $3,061,000 | $3,545,000 | $382,000 | $388,000 |
| Stock Based Compensation | $1,540,000 | $550,000 | $569,000 | $606,000 |
| Amortization Of Securities | $-9,000 | $-111,000 | $0 | - |
| Depreciation Amortization Depletion | $445,000 | $872,000 | $628,000 | $619,000 |
| Depreciation And Amortization | $445,000 | $872,000 | $628,000 | $619,000 |
| Gain Loss On Investment Securities | $2,631,000 | $-5,654,000 | - | - |
| Net Income From Continuing Operations | $-22,386,000 | $-12,978,000 | $-13,316,000 | $-20,275,000 |
| Change In Other Working Capital | - | $-997,000 | $281,000 | $1,643,000 |
| Amortization Cash Flow | - | $100,000 | $100,000 | $100,000 |
| Amortization Of Intangibles | - | $100,000 | $100,000 | $100,000 |
| Depreciation | - | $600,000 | $600,000 | $500,000 |
| Gain Loss On Sale Of PPE | - | $0 | $2,000 | $0 |
| Asset Impairment Charge | - | - | $117,000 | $93,000 |
| Proceeds From Stock Option Exercised | - | - | - | $0 |
| Unrealized Gain Loss On Investment Securities | - | - | - | $-1,000 |
| Changes In Account Receivables | - | - | - | - |
Fetched: 2026-06-22